Clearside Biomedical Inc [CLSD] stock is trading at $1.23, down -8.89%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CLSD shares have gain 26.80% over the last week, with a monthly amount glided 20.59%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Clearside Biomedical Inc [NASDAQ: CLSD] stock has seen the most recent analyst activity on August 21, 2024, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $6. Previously, Oppenheimer started tracking the stock with Outperform rating on June 25, 2024, and set its price target to $5. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $10 on July 29, 2021. ROTH Capital initiated its recommendation with a Buy and recommended $8 as its price target on May 13, 2020. Needham downgraded its rating to Hold for this stock on August 09, 2019. In a note dated November 05, 2018, Stifel downgraded an Hold rating on this stock.
Clearside Biomedical Inc [CLSD] stock has fluctuated between $0.65 and $2.12 over the past year. Clearside Biomedical Inc [NASDAQ: CLSD] shares were valued at $1.23 at the most recent close of the market.
Analyzing the CLSD fundamentals
Clearside Biomedical Inc [NASDAQ:CLSD] reported sales of 7.52M for the trailing twelve months, which represents a drop of -91.16%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -3.42%, Pretax Profit Margin comes in at -4.45%, and Net Profit Margin reading is -4.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.99, Equity is 1.7 and Total Capital is -0.92. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.67.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1533 points at the first support level, and at 1.0767 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3433, and for the 2nd resistance point, it is at 1.4567.
Ratios To Look Out For
For context, Clearside Biomedical Inc’s Current Ratio is 5.07. Also, the Quick Ratio is 5.07, while the Cash Ratio stands at 3.1. Considering the valuation of this stock, the price to sales ratio is 12.23.
Transactions by insiders
Recent insider trading involved Chong Ngai Hang Victor, Chief Medical Officer, that happened on Jun 24 ’24 when 23500.0 shares were purchased. Director, YERXA BENJAMIN R completed a deal on May 15 ’24 to buy 7813.0 shares. Meanwhile, Director Gibney Anthony S bought 93290.0 shares on Apr 18 ’24.
